<DOC>
	<DOC>NCT00237211</DOC>
	<brief_summary>To investigate the safety and efficacy of letrozole monotherapy at a dose of 2.5 mg/day in postmenopausal patients with breast cancer, and to determine the blood concentrations of letrozole and hormones.</brief_summary>
	<brief_title>Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Patients with histologically documented breast cancer. Patients with hormone receptor (ER and/or PgR) status of positive or unknown Patients who have been amenorrheic for the preceding 12 months or more. Patients who are 20 years or older and younger than 75 years. Patients with a history of postoperative adjuvant therapy or a history of endocrine therapy with tamoxifen for the treatment of progression or recurrence of the lesion. The endocrine therapy, however, should not exceed one regimen. Patients with progressing lesions. Patients with sufficient organ function to evaluate the safety Patients whose performance status (PS) is classified in 0ï½ž2. Patients who have no residual effects from previous treatments Patients with other concurrent or previous malignant disease (excluding uterine carcinoma insitu). Patients with hypercalcemia and uncontrollable cardiac disease (including a history of serious cardiac disease) Patients who have previously received aromatase inhibitor. Patients who have lymphangitistype lung metastasis or symptomatic brain metastasis. Other protocoldefined inclusion / exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>letrozole</keyword>
	<keyword>breast cancer</keyword>
</DOC>